Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With ...

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk's (NYSE:NVO) was ...

LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, executives are taking another look at the data but steering clear of making hard ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.

We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to ...

Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

NEW YORK, NY / ACCESS Newswire / February 23, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Long-Term Pick. In this article, we will summarize ...

Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects ...